Valuation: RVL Pharmaceuticals plc

Market Cap 3L 3L 3L 3L 5L 3.2Cr 5L 33.36L 12.84L 1.64Cr 12.55L 12.28L 5.25Cr P/E 2021
-1.12x
P/E 2022 -1.95x
Enterprise Value 1.33Cr 1.17Cr 1.11Cr 1Cr 1.89Cr 127.33Cr 1.91Cr 13Cr 5.1Cr 65Cr 4.99Cr 4.88Cr 208.7Cr EV / Sales 2021
5.55x
EV / Sales 2022 2.49x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
1 week 0
Extreme 1.0E-6
0
1 month 0
Extreme 1.0E-6
0
Current year 0
Extreme 1.0E-6
0
1 year 0
Extreme 1.0E-6
0
3 years 0
Extreme 1.0E-6
0.19
5 years 0
Extreme 1.0E-6
3.29
10 years 0
Extreme 1.0E-6
9.9
Manager TitleAgeSince
Chief Operating Officer 44 01/01/2016
Human Resources Officer - 01/01/2016
Date Insider Type Main position Quantity % Market Cap. Importance
19/10/23
Altchem Ltd.
SellCompany 1,41,22,659 12.6767%
19/10/23
Altchem Ltd.
SellCompany 1,41,22,659 12.6767%
18/10/23
Altchem Ltd.
SellCompany 34,21,537 3.0712%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 111
+4.16%-0.36%+49.37%+94.17% 7.45TCr
+0.26%+1.41%+28.00%+81.28% 6.01TCr
-0.76%+2.39%+9.10%+35.15% 4.82TCr
-0.05%+0.37%+41.54%+36.65% 4.43TCr
+0.38%+7.61%+339.53%+641.55% 4.4TCr
+0.18%+0.26%+7.41%+103.45% 4.16TCr
-0.67%+0.17%+7.60%+46.37% 3TCr
+4.77%+6.16%+36.77%+22.78% 2.93TCr
-1.29%-3.55%-20.74%+352.04% 2.49TCr
Average +0.59%+1.38%+55.40%+157.05% 3.97TCr
Weighted average by Cap. +0.87%+1.53%+59.65%+147.62%

Financials

2021 2022
Net sales 1.75Cr 1.54Cr 1.46Cr 1.32Cr 2.48Cr 167.8Cr 2.52Cr 17Cr 6.72Cr 86Cr 6.57Cr 6.43Cr 275.03Cr 4.97Cr 4.38Cr 4.15Cr 3.75Cr 7.06Cr 476.74Cr 7.15Cr 50Cr 19Cr 243.72Cr 19Cr 18Cr 781.37Cr
Net income -6.49Cr -5.72Cr -5.42Cr -4.89Cr -9.22Cr -622.47Cr -9.34Cr -65Cr -25Cr -318.22Cr -24Cr -24Cr -1.02TCr -5.17Cr -4.55Cr -4.31Cr -3.89Cr -7.34Cr -495.64Cr -7.43Cr -52Cr -20Cr -253.38Cr -19Cr -19Cr -812.34Cr
Net Debt 72.01L 63.41L 60.08L 54.24L 1.02Cr 69Cr 1.04Cr 7.19Cr 2.77Cr 35Cr 2.7Cr 2.64Cr 113.16Cr 1.29Cr 1.14Cr 1.08Cr 97.51L 1.84Cr 124.13Cr 1.86Cr 13Cr 4.97Cr 63Cr 4.86Cr 4.76Cr 203.45Cr
Logo RVL Pharmaceuticals plc
RVL Pharmaceuticals plc is a pharmaceutical company focused on developing and commercializing eye care and medical aesthetics products. The Company is focused on developing and commercializing products for an underserved patient population in ocular medicine and medical aesthetics. It operates in one business segment which focuses on developing and commercializing pharmaceutical products. The Company is commercializing Upneeq for treating acquired blepharoptosis (low-lying eyelids) in adults and is developing Arbaclofen ER tablets for alleviating spasticity in multiple sclerosis patients. Their healthcare provider customers include optometrists, ophthalmologists, oculoplastic surgeons, facial plastic surgeons, dermatologists, and other qualified practitioners. The target patient population comprises adults with droopy or low-lying eyelids, primarily females. Its commercial operations are managed by wholly owned subsidiaries, RVL Pharmaceuticals, Inc., and RVL Pharmacy, LLC.
Employees
125
Date Price Change Volume
29/26/29 $0.000001 -.--% 3,600
23/26/23 $0.000001 -.--% 1,720
  1. Stock Market
  2. Stocks
  3. RVLPQ Stock